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Abstract
Activation and proliferation of glial cells and their progenitors is a key process of
neuroinflammation associated with many neurodegenerative disorders. Under neuropathological
conditions where glial cell activation and proliferation is evident, controlling the population of glia
might be of therapeutic importance. The proliferative action of the cytokine tumor necrosis factor
alpha (TNFα) on microglia has been reported, but the molecular mechanism of TNFα regulation of
glial cell proliferation is largely unknown. Using a model of organotypic hippocampal-entorhinal
cortex (HEC) slice culture, we investigated the role of ATP-P2X7 receptor signaling in glial
proliferation by TNFα. Populations of proliferating cells in HEC culture were labeled with 5-
bromo-2′-deoxyuridine (BrdU). Treatment with TNFα induced strong expression of P2X7 receptor
mRNA and immunoreactivity in BrdU+ cells while markedly increasing proliferation of BrdU+
cells. In addition, TNFα increased aquaporin 4 (AQP4) expression, an ion channel involved in
glial proliferation. The proliferative action of TNFα was attenuated by blocking the P2X7
receptors with the specific antagonists oxATP, BBG and KN62, or by lowering extracellular ATP
with ATP hydrolysis apyrase. Basal proliferation of BrdU+ cells was also sensitive to blockade of
ATP-P2X7 signaling. Furthermore, TNFα activation of P2X7 receptors appear to regulate AQP4
expression through protein kinase C cascade and down regulation of AQP4 expression can reduce
TNFα-stimulated BrdU+ cell proliferation. Taken together, these novel findings demonstrate the
importance of ATP-P2X7 signaling in controlling proliferation of glial progenitors under the
pathological conditions associated with increased TNFα.
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INTRODUCTION
The activation and proliferation of glial cells in response to brain insults such as brain
trauma, ischemia, and inflammation is an active process that has both beneficial and
detrimental effects on brain repair and recovery. Microglia are the predominant immune cell
of the CNS and are first to be activated following an insult, rapidly migrating to the injury
site and initiating further glial reaction and communication with the immune system (Robel
et al., 2011). Similarly, astrocytes are the most abundant cell type in the CNS and react
promptly to a variety of CNS pathologies leading to astrogliosis (Eng and Ghirnikar, 1994).
Astrogliosis is characterized by an aberrant proliferation of astrocytes as well as an increase
in the number of intermediate filaments with accompanying cellular hypertrophy. These
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activated astrocytes and activated microglia then release proinflammatory cytokines/
mediators such as tumor necrosis factor alpha (TNFα), interleukin (IL)-1β, and inducible
nitric oxide synthase (Griffin, 2006; Dheen et al., 2007), contributing to further brain
inflammation and neurodegeneration (Scholz and Woolf, 2007; Inoue and Tsuda, 2009).
Thus, studying the mechanism by which glial cells proliferate in response to neurological
insults may provide valuable information on modulating glial cells in the compromised
brain.
TNFα is a proinflammatory cytokine involved in systemic inflammation and induces
neuronal cell death through several mechanisms such as direct apoptotic action (Yu et al.,
2006) and inhibition of glutamate uptake leading to increased extracellular glutamate levels
and excitotoxicity (Zou and Crews, 2005; Zou and Crews, 2006). TNFα exerts its biological
effects through activation of two distinct receptor subtypes, TNFR1 and TNFR2 (Wajant,
2003), and TNFα and its receptors are expressed on progenitor cells of the rat hippocampus
(Klassen et al., 2003; Iosif et al., 2006). Recent evidence suggests that TNFα positively or
negatively modulates progenitor cell proliferation. Indeed, TNFα may up-regulate the
proliferation and differentiation of neural progenitors in the subventricular zone after CNS
injury (Wu et al., 2000; Katakowski et al., 2007), which may be mediated via IKK/NF-κB
signaling (Widera et al., 2006). On the other hand, TNFα has also been found to suppress
neural progenitor proliferation and neurogenesis through TNFR1 signaling (Iosif et al.,
2006) and to compromise the survival of hippocampal progenitors in vitro (Cacci et al.,
2005).
Cellular proliferation, especially the propagation of glia, is tightly controlled by complex
microenvironments through cell-cell interactions and specific receptor families. The P2X7
receptor (P2X7R) is a member of the purinergic P2X family of ATP-gated ion channels, and
a high level of extracellular ATP is required for the activation of P2X7Rs. This receptor
mediates the influx of Na+ and Ca2+ during neuronal activation and the concomitant efflux
of K+ (Gudipaty et al., 2003; Witting et al., 2004). In addition, sustained activation of
P2X7Rs may generate non-selective pores that are permeable to small molecules up to 900
Da in size (Virginio et al., 1999; Di Virgilio et al., 2001). Although expression of the P2X7R
is primarily associated with immune and hematopoietic cells (Surprenant et al., 1996; Di
Virgilio et al., 2001), its mRNA or protein has been identified in all brain cell types in the
CNS (Ferrari et al., 1999; Choi et al., 2007; Yu et al., 2008). Importantly, the P2X7R is
highly expressed on microglia and activation of these receptors is correlated with release of
the proinflammatory cytokines IL-1β (Ferrari et al., 1997; Lister et al., 2007) and TNFα
(Hide et al., 2000; Lister et al., 2007). The functional responses of P2X7R activation by ATP
are associated with ongoing cellular damage and chronic brain inflammation. Indeed, recent
experimental evidence indicates that stimulation of P2X7Rs mediate ATP-induced apoptosis
through microglial production of superoxide (Parvathenani et al., 2003; Raouf et al., 2007).
In addition, expression of the P2X7R is up-regulated in a transgenic mouse model of
Alzheimer’s disease (Parvathenani et al., 2003) and amyloid-β-treated rat microglia
(McLarnon et al., 2006). The P2X7R might also play a role in microglial proliferation since
down-regulation of the P2X7R is involved in LPS-induced reduction of microglial
proliferation (Bianco et al., 2006). Thus, identification of the role of the P2X7R in cytokine-
induced inflammation will provide further insight into its role in the pathological brain.
Aquaporin 4 (AQP4) is the most abundant water channel protein in the CNS (Jung et al.,
1994) and strongly expressed in astrocytes (Nielsen et al., 1997). Recent studies indicate that
AQP4 plays a role in regulating neural stem cell proliferation and neurogenesis (Saadoun et
al., 2005; Kong et al., 2008; Kong et al., 2009) as well as proliferation of astrocytes in
striatal primary cultures (Kuppers et al., 2008) and cocaine-treated animals (Xie et al.,
2009). The expression of AQP4 protein may be regulated by P2X7 activation (Lee et al.,
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2008) and the AQP4-dependent Ca2+ signaling may be mediated, in part, by autocrine
purinergic signaling (Thrane et al. 2011), suggesting an interaction between P2X7 and
AQP4. In support, a study using a single intranigral injection of LPS found that AQP4
mRNA and protein are expressed in reactive microglial cells (Tomas-Camardiel et al.,
2004). Furthermore, TNFα increases proliferation and AQP4 expression in astrocytes (St
Hillaire et al., 2005; Alexander et al., 2008). However, little research has been performed to
determine whether AQP4 is involved in glial progenitor proliferation regulated by ATP-
P2X7 or TNFα signaling.
The aim of this study was to investigate whether ATP-P2X7R signaling is involved in
TNFα-stimulated proliferation of glial cells labeled by the dividing cell marker BrdU. The
model of organotypic rat hippocampal-entorhinal cortical (HEC) slice culture was used in
the present study. Our results demonstrated that ATP-P2X7 receptor signaling interacts with
AQP4 to control the proliferative actions of cytokine TNFα on proliferating glial cells.
MATERIALS AND METHODS
Hippocampal-entorhinal cortical slice culture
All protocols followed in this study were approved by the Institutional Animal Care Use
Committee of The University of North Carolina at Chapel Hill and were in accordance with
National Institute of Health regulations for the care and use of animals in research.
Organotypic hippocampal-entorhinal cortical (HEC) slice cultures were prepared from
Sprague-Dawley rat neonates according to the techniques of Stoppini and colleagues
(Stoppini et al., 1991) with modifications. Briefly, rat neonates at postnatal day 7 were
decapitated, brain removed and hippocampal-entorhinal complex dissected in Gey’s buffer.
Slices were transversely cut with McIlwain tissue chopper at a thickness of 375 μm and
placed onto a 30 mm diameter membrane tissue insert, 8-10 slices/tissue insert. Slices were
cultured with medium containing 75% MEM with 25 mM HEPES and Hank’s salts + 25%
horse serum + 5.5 g/L glucose + 2 mM L-glutamine in a humidified 5% CO2 incubator at
36.5°C.
5-Bromo-2′-deoxyuridine (BrdU) labeling, immunohistochemistry and quantification
HEC slices at 10 days in vitro (DIV) were treated with BrdU (50 μM, Sigma-Aldrich) for 24
hr and then returned to BrdU-free culture medium up to the end of experiments. BrdU was
left in the culture medium through the end of experimentation in a time course study of
control and TNFα-treated cultures. Various treatments and experimental designs were
performed in the BrdU-treated slices in a BrdU-free medium. At the end of each treatment,
the slices were removed and fixed with 4% paraformaldehyde + 5% sucrose in 0.1 M PBS
overnight at 4°C. BrdU immunohistochemistry follows the method described elsewhere
(Nixon and Crews, 2002) with a slight modification. For BrdU-positive cell quantification,
the pixel density of BrdU immunoreactivity in the region of hippocampal dentate gyrus was
determined by Bioquant imaging software as described previously (Crews et al., 2006).
Drug treatments
All chemicals, except for those specified, were purchased from Sigma-Aldrich. BrdU-treated
slices were assigned to the experimental groups treated with TNFα (25 ng/ml, R&D
Systems, Minneapolis, MN) in the presence or absence of other pharmacological reagents
including ATPase apyrase (25 and 50 U/ml), BzATP (10, 50, 100 and 300 μM), oxATP (10,
50, 100 and 300 μM), brilliant blue G (BBG, 100 μM), H-7 (50 μM), tetraethylammonium
(TEA, 50 and 100 μM), suramin (100 μM) and ivermectin (300 μM), NTPDase inhibitor
ARL 67156 (10 and 50 U/ml, Tocris, Ellisville, MO), KN62 (50 μM, Chemicon), ERK
inhibitor PD 98059 (50 μM, Chemicon) and p38MAPK inhibitor SB 203580 (50 μM,
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Chemicon) in BrdU-free medium. At the end of the experiment, all slices were removed for
other purposes.
Double immunofluorescence and confocal analysis
Free-floating slices were processed for double immunofluorescence staining. The primary
antibodies used were as follows: mouse or rat anti-BrdU for progenitor cells (1:500);
neuronal-specific nuclear protein (NeuN) for neurons (1:500, Chemicon), Iba-1 (1:1000,
Wako, Richmond, VA) or ED-68 (1:100, Serotec, Raleigh, NC) for microglia, rabbit anti-
GFAP (1:1000, Dako, Carpinteria, CA) or mouse anti- GFAP (1:1000, Sigma-Aldrich) for
astrocytes, rabbit anti-P2X7 receptor C-terminus (1:100, Sigma-Aldrich or Santa Cruz, Santa
Cruz, CA). Alexa Fluor 594 anti-rabbit and Alexa Fluor 488 anti-mouse IgG (1:1000,
Invitrogen, Carlsbad, CA) were secondary. A negative control in which the primary
antibody was omitted was used to assess nonspecific binding of the secondary antibody. All
slices were incubated with primary antibody for 48 hr at 4°C and 2 hr with second antibody
at room temperature. Confocal analysis was performed using a LeicaSP2 AOBS Upright
Laser Scanning Confocal in the Michael Hooker Microscopy Facility at UNC. The co-
localization of BrdU or P2X7R with neuronal specific (NeuN), microglial specific (Iba-1/
ED-68) or astrocytic specific (GFAP) proteins was analyzed with confocal microscopy. For
quantification of BrdU+/Iba-1+ cell co-localization, a series of sections at the Z-plane were
collected at 1-2 μm thickness, and the number of cells was counted at two adjacent sections
(1800-3600 cells in each group).
AQP4 knockdown with siRNA
Rat AQP4 siRNA (Santa Cruz, Cat# sc-156007) was used to knock down AQP4 expression.
Preparation of transfection reagents and transfection were performed according to the
manufacturer’s siRNA transfection protocol. Briefly, after 10 min of equilibration at room
temperature, siRNA solution was combined with Lipofectamine 2000 solution to form
siRNA liposomes for a further 20 min at room temperature. The transfection mixture was
added to serum-free N2 medium at a final concentration of 20 nM siRNA + 8 μl
Lipofectamine 2000 in a total volume of 1.5 ml (500 μl on top of slices and 1 ml at bottom
of the cultures). Vehicle controls were treated with the same N2 medium containing
Lipofectamine only or with negative control siRNA (Ambion). After 24 hr transfection,
siRNA-containing medium was replaced with regular serum-free N2-supplemented medium
and the slices were cultured for another 48 hr in the presence of TNFα. At the end of
experiments, the slices were removed and BrdU+ cell determined.
RNA isolation, reverse transcription and real time quantitative RT-PCR
For each specific experiment, the slices were removed at the end of experiment, rinsed with
cold PBS, and followed by total RNA purification using the RNeasy Mini Kit (Qiagen,
Valencia, CA). The total amount of RNA was quantified by spectrophotometry at 260 nm.
For reverse transcription, 2 μg of RNA was used to synthesize the first strand of cDNA
using random primers (Invitrogen) and reverse transcriptase Moloney murine leukemia virus
(Invitrogen). After a 1:2 dilution with water, 2 μl of the first strand cDNA solution was used
for RT-PCR. The primer sequences for real time RT-PCR were designed by Integrated DNA
Technologies (Coralville, Iowa). The following primers were used: for P2X7 receptor,
forward 5′-TGTCCCTATCTCTCCACGACTCAC-3′ and reverse 5′
ATTTCCACACTGGCACCAACTCGG-3′; for AQP4, forward 5′-
CCATTAACTGGGGCTCAG-3′ and reverse 5′-AACTGCAGGGCCAAAGGATCG-3′ and
for β-actin, forward 5′-CTACAATGAGC-TGCGTGTGGC-3′ and reverse 5′-
CAGGTCCAGACGCAGGATGGC-3′. SYBER Green Supermix (AB system, UK) was
used as a RT-PCR solution. The real time RT-PCR was run with initial activation for 10 min
at 95°C and followed by 40 cycles of denaturation (95°C, 40 s), annealing (58°C, 45 s) and
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extension (72°C, 40 s). All experiments were run in triplicate. The threshold cycle (CT) of
each target product was determined and normalized to internal standard β-actin. Difference
in CT · values (CT) of two genes was calculated [difference = 2−(CT of target genes − CT of
β-actin) = 2−CT], and the result was expressed as the percentage or fold difference compared
to control.
Statistical Analysis
Statistical significance was analyzed by ANOVA and Student’s t test. Experimental results
are presented as a mean ± SEM. Differences were considered to be statistically significant at
a p<0.05.
RESULTS
Proliferation of BrdU+ cells in HEC slices
To monitor cell proliferation, slices at 10 DIV were treated with BrdU (50 μM) and BrdU
immunohistochemistry was used to detect BrdU+ cells. The pixel density of BrdU+
immunoreactive (IR) cells was measured in the hippocampal dentate gyrus with computer-
assisted BioQuant Imaging software throughout the study (Figure 1-A). BrdU
immunohistochemistry revealed widespread proliferation of BrdU+ cells in HEC slices.
However, the distribution of these cells on the surface of the slice was heterogeneous as
some regions, such as the dentate gyrus and layer 4 of entorhinal cortex, had a dense
population of BrdU+ cells, whereas others had fewer BrdU+ cells (Figure 1-A). The time
course study of proliferation found that the BrdU+IR increased progressively over time
suggesting that proliferating cells were actively undergoing cell cycle progression under the
culture conditions used in the present study (Figure 1-B).
TNFα stimulates robust proliferation of BrdU+/Iba-1+ cells
We investigated whether TNFα modulates proliferation of BrdU+ cells in this model. The
BrdU-treated slices were incubated with BrdU-free medium containing TNFα (25 ng/ml) for
various time periods and BrdU+IR was determined. As shown in Figure 2 (top panel), TNFα
stimulated a rapid and robust increase in BrdU+ cell proliferation. TNFα treatment increased
BrdU+IR by 160%, 375%, 283%, and 213% at 8, 24, 48, and 96 hr, respectively.
To identify cellular phenotypes, we used confocal microscopy and double fluorescent
immunostaining for BrdU and cell type specific markers (Iba-1 for microglia; NeuN for
neurons; GFAP for astrocytes). In a representative experiment with TNFα treatment for 48
hr, BrdU+IR was markedly increased in the TNFα-treated group (Figure 2, bottom panel A-
B). Confocal analysis of double fluorescent immunostaining revealed that approximately
50% of BrdU+ cells co-expressed Iba-1 (Figure 2, bottom panel C). BrdU+ cells rarely co-
expressed the neuronal marker NeuN or astrocytic marker GFAP (data not shown). Thus,
about 50% of proliferating cells are Iba-1+ microglia-like cells, and the remaining 50% of
proliferating cells that were not identified by cell markers use. The percentage of BrdU+
cells co-expressing Iba-1 were significantly increased from 48% in control to 90% in TNFα-
treated slices at the 48 hr time point (Figure 2, bottom panel D).
ATP-P2X7 receptor signaling controls the basal proliferation of BrdU+ cells
We performed experiments to directly test the hypothesis that endogenous ATP could be
released by cells in response to damage or other physiological responses that may drive the
basal proliferation of BrdU+ cells by activating P2X7Rs. The first series of experiments
examined the growth promoting role of endogenous ATP-P2X7 receptor signaling by
manipulating the extracellular ATP level with ATPase apyrase or the NTPDase inhibitor,
ARL 67156. The results revealed that apyrase significantly reduced BrdU+ cell proliferation
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at the concentrations 10 and 50 U/ml, and ARL 67156 increased BrdU+ cell proliferation at
the concentrations 10 and 50 U/ml (Figure 3A). The second set of experiments tested the
effects of the P2X7R agonist BzATP (10, 50, 100, and 300 μM) and the antagonist oxATP
(10, 50, 100, and 300 μM) on basal proliferation of BrdU+ cells. Treatment of the slices
with BzATP for 48 hr resulted in a dose-dependent increase in BrdU+ cell proliferation
whereas treatment with oxATP reduced BrdU+ cell proliferation. Other P2X7R, antagonists,
such as KN62 (50 μM) and Brilliant Blue B (BBG, 100 μM) as well as P2X4R antagonists
suramin (100 μM) and agonist ivermectin (50 μM) were also tested. Both KN62 and BBG
significantly inhibited basal proliferation of BrdU+ cells, but suramin and ivermectin has no
effect on proliferation (Figure 3C). Further characterization of the cellular expression of
P2X7Rs with double immunofluorescence staining and confocal analysis revealed that
P2X7Rs were widely expressed on proliferating cells labeled by BrdU (Figure 4, panel A).
Consistent with other reports (Xiang and Burnstock, 2005; Choi et al., 2007), P2X7Rs were
expressed on microglia, neurons, and astrocytes in the cultured slices (Figure 4, panel B-D).
These results indicate that endogenous ATP could directly stimulate P2X7Rs on
proliferating cells labeled by BrdU and drive BrdU+ cell proliferation under the culture
conditions used in the present study.
TNFα induces P2X7 receptor expression
We hypothesized that the proliferative actions of TNFα may be mediated through ATP-
P2X7 receptor signaling in this model. Double immunofluorescence staining revealed that
P2X7R+IR was strongly co-expressed on BrdU+ cells in slices treated with TNFα (Figure
5A). RT-PCR analysis found that P2X7R mRNA levels were elevated 10-fold at 24 hr and
8-fold at 48 hr of treatment with TNFα (Figure 5B). Examination of the effects of TNFα on
NTPDase mRNA expression with several isoforms of NTPDases revealed that TNFα
treatment did not significantly alter NTPDase mRNA levels (data not shown).
Proliferative effect of TNFα is sensitive to ATPase and blockade of P2X7 receptors
We further investigated the role of ATP-P2X7 receptor signaling on the proliferative actions
of TNFα on BrdU+ cell proliferation. All P2X7R antagonists assessed effective blocked
TNFα-stimulated BrdU+ cell proliferation. Treatment with TNFα for 48 hr increased BrdU
+IR by 235% relative to control, and the presence of P2X7R antagonists reduced TNFα-
stimulated BrdU+IR cells by 43%, 56% and 73% with KN62 (50 μM), BBG (100 μM), and
oxATP (100 μM), respectively (Figure 6). Among the P2X7R antagonists tested, oxATP was
the most effective in blocking TNFα-stimulated BrdU+ cell proliferation. The P2X4R
antagonist suramin (100 μM) did not alter TNFα-stimulated BrdU+ cell proliferation (Figure
6). These results support a specific role of P2X7R in regulating TNFα-stimulated
proliferation of cells labeled by BrdU in this model.
Since levels of extracellular ATP could limit activation of P2X7R, we could not exclude the
possibility that TNFα may increase ATP release resulting in enhanced activation of P2X7R.
Administration of the ATPase apyrase, which lowers extracellular ATP levels, reduced
TNFα-stimulated proliferation of BrdU+ cells by 52% and 82% at concentrations of 25 U/ml
and 50 U/ml, respectively (Figure 6). Taken together, these results demonstrate that ATP-
P2X7 signaling mediates the proliferative action of TNFα on BrdU+ cells, in which BrdU+/
Iba-1+ cells account for the increases in this model.
Involvement of AQP4 and downstream signaling pathways in proliferative action of TNFα
We examined the possibility that TNFα activation of P2X7Rs might regulate AQP4
expression and subsequently influence the proliferative actions of TNFα. We first measured
AQP4 mRNA expression in slice cultures treated with TNFα in the absence or presence of
the P2X7R antagonist oxATP (100 μM) or protein kinase C (PKC) inhibitor, H-7 (50 μM).
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Treatment with TNFα induced strong expression of AQP4 mRNA that was completely
blocked by both oxATP and H-7 (Figure 7A). These data suggest that TNFα induction of
AQP4 gene expression is associated with activation of P2X7Rs and downstream PKC
cascade signaling. Consistent with the AQP4 mRNA data, BrdU+IR analysis from the same
experiment revealed that the proliferative actions of TNFα were completely abolished by
both oxATP and H-7 (Figure 7B). To directly test the role of AQP4 in the proliferative
actions of TNFα, the post-BrdU treated slices were pretreated with AQP4 inhibitor TEA (50
and 100 μM) or knockdown AQP4 by using siRNA during TNFα treatment. As shown in
Figure 7B, the AQP4 inhibitor TEA dose-dependently reduced TNFα-induced BrdU+ cell
proliferation by 41% and 63%, respectively. Similar results were also obtained by knocking
down AQP4 with siRNA. Furthermore, the role of P2X7R downstream signaling cascade
including ERK and p38MAPK in the proliferative action of TNFα was also evaluated in the
present study. Both the ERK inhibitor, PD 98059 (50 μM), and the p38MAPK inhibitor, SB
203580 (50 μM), significantly blocked TNFα-stimulated proliferation of BrdU+ cells by
38% and 43%, respectively (Figure 8). Taken together, these results suggest interactive role
between activation of P2X7Rs and AQP4 in regulation of proliferative actions of TNFα in
this model.
DISCUSSION
The present study investigated the growth-promoting role of ATP-P2X7 receptor signaling
in BrdU+ proliferating cells in a model of organotypic brain slice culture. This series of
experiments is the first to demonstrate that: (1) P2X7 receptors are widely expressed on
BrdU-labeled proliferating cells; (2) the proinflammatory cytokine TNFα exerts a strong
proliferative action on BrdU+ cells in parallel with enhanced expression of P2X7Rs; (3)
basal and TNFα- stimulated proliferation of BrdU+ cells is sensitive to the blockade of ATP-
P2X7 receptor signaling with ATPase apyrase or P2X7R antagonists; and (4) AQP4
expression may be regulated by activation of P2X7Rs and play a role in regulating the
proliferative actions of TNFα. These novel findings demonstrate for the first time that ATP-
P2X7 receptor signaling plays a critical role in controlling proliferation of glial progenitors.
The growth-promoting role of P2X7R signaling has been reported in several models. An
earlier study demonstrated that transfection of P2X7Rs into human lymphoblastoid cells that
lacked P2X7Rs stimulates cell proliferation in response to endogenously released ATP
(Baricordi et al., 1999). ATP-P2X7R signaling plays an important role in controlling
activation and proliferation of microglial cells. Indeed, blockade of P2X7Rs with
antagonists, treatment with the ATP hydrolase apyrase, and down-regulation of P2X7Rs
with siRNA significantly decrease microglial cell proliferation in cultured N9 cell line
(Bianco et al., 2006). Activation and proliferation of microglia via exposure to LPS can be
attenuated by administration of P2X7R antagonists (Bianco et al., 2006; Choi et al., 2007).
Recently, Monif and colleagues (Monif et al., 2009) reported that overexpression of P2X7Rs
in the absence of a pathological insult is sufficient to drive the activation and proliferation of
microglial cells in rat primary hippocampal cultures. Furthermore, pore conductance rather
than cation channels mediate the trophic effects of increased P2X7R expression. Consistent
with these reports, our findings demonstrate the strong growth promoting role of ATP-P2X7
receptor signaling in proliferating cells labeled by BrdU in an organotypic brain slice culture
model used to identify and study proliferation and neurogenesis (van Praag et al., 2002;
Noraberg et al., 2005; Namba et al., 2007). TNFα-induced increases in proliferation of BrdU
+ cells are completely abolished by ATP hydrolase apyrase and blockade of P2X7Rs with
several antagonists, including oxATP, KN62, and BBG. Conversely, administration of the
potent P2X7R agonist BzATP enhanced basal proliferation of BrdU+ cells. Our results
demonstrate that oxATP appears to be the most effective in blocking TNFα proliferative
action as a concentration of 300 μM abolished more than 90% BrdU+ cell proliferation.
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KN62, an inhibitor of calcium/calmodulin-dependent protein kinase II, has been described
as a potent antagonist at the native P2X7-like receptor of human lymphocytes (Gargett and
Wiley, 1997), but is inactive at rat P2X7Rs (Humphreys et al., 1998). Several recent studies
have further confirmed that KN62 up to 10 μM is ineffective in blocking BzATP-stimulated
responses at the rat P2X7R, but can block mouse P2X7Rs (Hibell et al., 2001; Michel et al.,
2008; Donnelly-Roberts et al., 2009). Our results show that KN62 effectively reduces
TNFα-stimulated BrdU+ cell proliferation in rat brain slice culture. It is not clear whether
this is the result of specific actions of KN62 at the concentration used on P2X7Rs. Thus, we
could not exclude the possibility that KN62 blocked the proliferative actions of TNFα
through inhibition of calcium/calmodulin-dependent protein kinase II. Further experiments
such as testing the direct effect of KN62 on BzATP-stimulated BrdU+ cell proliferation may
be needed to clarify whether KN62 is effective in blocking P2X7Rs in this model.
Our results found that the P2X4R antagonist suramin at concentration of 100 μM is
ineffective in blocking basal and TNFα-stimulated BrdU+ cell proliferation. Suramin has
been found to be a non-selective antagonist at native P2X and P2Y receptors (Ralevic and
Burnstock, 1998; Lambrecht, 2000) and also has potency at the P2X7R (Hibell et al., 2001).
Considering the fact that suramin is a wide range P2 antagonist, further experiments such as
a dose-dependent study as well as BzATP stimulation may be needed to clarify whether
suramin can effectively block BrdU cell proliferation in this model.
TNFα is known to promote glial cell proliferation (Arnett et al., 2001; Mander et al., 2006),
while inhibiting neural progenitor cell proliferation and neurogenesis (Monje et al., 2003;
McCoy and Tansey, 2008). Although the mechanisms by which TNFα increases microglial
cell proliferation remain unclear, some studies have reported that oxidative stress and
MAPK are involved (Mander et al., 2006). Direct evidence linking ATP-P2X7 receptor
signaling to the proliferative action of TNFα is also lacking. Our results reveal for the first
time that TNFα treatment strongly upregulates gene and protein expression of P2X7Rs in
proliferating cells labeled by BrdU in a brain slice culture as 90% of BrdU+ cells co-
expressed the microglial marker Iba-1 after TNFα stimulation. The proliferative effects of
TNFα on microglia are effectively blocked by administration of either ATP hydrolase
apyrase or P2X7R antagonists. These findings clearly indicate that ATP-P2X7 receptor
signaling plays a critical role in mediating the proliferative actions of TNFα in this model.
Combined with the nature of slice culture modeling, these findings are quite relevant to
neuropathological conditions such as neuroinflammation, brain trauma, and ischemic
damage where there is increased release of cytokines such as TNFα and IL-1β as well as
increased endogenous ATP from damaged cells (Tansey and Goldberg, 2010; Rojo et al.,
2008). Microenvironments under these conditions are favorable for the proliferation of
microglia and astrocytes, which act as a danger/damage sensor and release cytokines and
ATP when activated. This self-propagation cycle could greatly exacerbate brain damage and
neuronal cell death. Thus, ATP hydrolase apyrase and P2X7R antagonists are effective in
inhibiting basal or TNFα-induced proliferation of BrdU-labeled cells and may have
significant implication for new therapeutic options that target ATP-P2X7 receptor signaling
in order to regulate proliferation of glial cells in response to neuroinflammatory insults.
Another significant finding in this study is that AQP4 expression is influenced by activation
of P2X7Rs and is involved in the proliferative actions of TNFα. AQP4 is the predominant
water channel proteins involved in maintaining water and ion homeostasis in physiological
and pathological conditions in the CNS. Both AQP4 and P2X7Rs are highly expressed on
astrocytes in the CNS (Cavazzin et al., 2006; La Porta et al., 2006). Recent work from other
laboratories indicate that AQP4 plays a role in regulating neural cell proliferation and
neurogenesis (Saadoun et al., 2005; Kong etal., 2008; Kuppers et al., 2008; Kong et al.,
2009) as well as proliferation of astrocytes in striatal primary cultures (Kuppers et al., 2008)
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and cocaine-treated animals (Xie et al., 2009). On the other hand, TNFα can increase AQP4
expression in astrocytes (St Hillaire et al., 2005; Alexander et al., 2008). However, there is
little information available regarding the interaction of AQP4 and P2X7Rs in the regulation
of cell proliferation. One study by Lee and colleagues (Lee et al., 2008) reported that
activation of P2X7Rs in astrocytes is associated with down-regulation of AQP4 in response
to brain injury, and pretreatment with the P2X7R antagonist oxATP abolished this down-
regulation. Under these conditions, down-regulation of AQP4 was a protective mechanism,
which may inhibit water influx to the cells and attenuate the acute cytotoxic brain edema
after brain injury. In contrast to this report, our data clearly indicate that the cytokine TNFα
increases both P2X7R and AQP4 gene expression that is accompanied by strong
proliferative action on BrdU+ cells. By blocking P2X7R activation with the antagonist
oxATP, TNFα induction of AQP4 mRNA expression was abolished, suggesting a role of
P2X7Rs in the regulation of AQP4 expression by TNFα. With regard to the regulation of
P2X7R or AQP4 expression, the literature has confirmed that TNFα up-regulates their
expression (St Hillaire et al., 2005; Alexander et al., 2008). In this regard, our results are
consistent with these reports. For the first time, we provide direct evidence of an interaction
of the P2X7R and AQP4 in the proliferative actions of TNFα. Indeed, TNFα- stimulated
proliferation of BrdU+ cells can be effectively blocked by down-regulating AQP4
expression or function with an AQP4 inhibitor or siRNA knockdown. It is not clear whether
reduction induced by inhibition of AQP4 is directly mediated through blocking AQP4 in
those BrdU+/Iba-1+ microglia or influenced by blocking AQP4 in the surrounding cells. A
recent study has indicated that AQP4 mRNA and protein can be expressed in reactive
microglial cells stimulated by LPS (Tomas-Camardiel et al., 2004). This would support our
data that TNFα-stimulated BrdU+/Iba-1+ microglia may express AQP4 in our model. Future
studies are needed to examine if TNFα-stimulated BrdU+/Iba-1+ microglia are co-
expressing AQP4 in this model.
Activation of P2X7Rs activate PKC that is associated with AQP4 expression (Kleindienst et
al., 2006). The PKC inhibitor H-7 used in the present study effectively blocked TNFα
induction of AQP4 mRNA expression as well as proliferation of BrdU+ cells. Activation of
PKC by TPA is reported to decrease AQP4 mRNA expression as well as water permeability
(Kleindienst et al., 2006). Although we did not examine the effects of TNFα on PKC,
blockade of TNFα induction of AQP4 mRNA expression as well as BrdU+ cell proliferation
by PKC inhibitor H-7 would suggest the involvement of PKC in the proliferative actions of
TNFα. These effects could occur either through activation of P2X7Rs and subsequent
activation of downstream signaling cascade including PKC, or direct activation of TNFα on
PKC as reported by many studies in different cell types (Zhou et al., 2006; Peng et al.,
2011). However, it has been reported that TNFα-induced increases in AQP4 expression may
be mediated by p38MAPK (St Hillaire et al. 2005) since we also note that the p38MAPK
inhibitor significantly blocked the proliferative actions of TNFα in this model. Together, our
data provide the evidence that AQP4 might be involved in TNFα-stimulated proliferation of
BrdU+ cells though activation of P2X7 receptors and a downstream signaling cascade that
involves PKC and p38MAPK as well as ERK, collectively resulting in alteration of AQP4
function. This blocking AQP4 with inhibitor or knockdown AQP4 with siRNA may be a
useful tool in preventing gliosis in certain neuropathological conditions.
In conclusion, our results indicate that basal proliferation of BrdU+ cells is sensitive to
blockade of ATP-P2X7 receptor signaling suggesting that endogenous ATP might be
released from slices during culture and drive the basal proliferation (Figure 9).
Administration of the proinflammatory cytokine TNFα exaggerates cell proliferation
through enhanced actions on P2X7R signaling (Figure 9). The proliferative action of TNFα
can be effectively blocked by lowering extracellular ATP with apyrase or by blocking
P2X7Rs with antagonists as well as by blocking AQP4 expression and downstream signaling
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cascades (Figure 9). These findings are particularly relevant to the neuropathological
conditions such as brain trauma, ischemia and neuroinflammation as well as several
neurodegenerative disorders, which involve increased ATP release and P2X7R expression as
well as cytokine release. The results of the studies herein warrant further experiments to test
pharmacological inhibition or stimulation of ATP-P2X7 receptor signaling as a therapeutic
strategy in these pathological conditions. Glial cells may respond to their
microenvironments by actively proliferating and releasing various factors, which may be
detrimental or beneficial to brain repair or recovery. Therefggore, targeting the ATP-P2X7
receptor signaling cascade may effectively control populations of proliferating glial cells and
protect neuronal cells. Two studies have recently demonstrated that in vivo administration of
the P2X7R antagonist BBG effectively blocked neuronal apoptosis triggered by P2X7R
stimulation in mouse models of Huntington’s disease (Diaz-Hernandez et al., 2009) and that
administration of BBG in a spinal cord injury model reduced abnormal morphology,
improved motor recover, and reduced the local activation of astrocytes and microglia (Peng
et al., 2009). Our findings may add another dimension to further support the effectiveness of
this strategy.
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Figure 1. Proliferation of progenitor cells labeled by BrdU in HEC slice
HEC slices at 10 DIV were treated with BrdU (50 μM) for 24 hr and fixed at different time
points. BrdU immunohistochemistry was used to visualize BrdU+ cells. The whole-mounted
HEC slice (A) shows the distribution of BrdU+ cells in slice after 4 day post-BrdU (total 14
DIV), with dense BrdU+ cells in dentate gyrus (DG) of the hippocampus and layer IV of
entorhinal cortex (ENT) (Scale bar = 500 μm). With computer-assisted imaging software,
BrdU+ cell immunoreactivity (IR) in the DG defined region defined in the box was
measured and quantified throughout study. Depicted in the graph (B) is the mean ± S.E.M.
of BrdU+IR measured from slices (n = 6) in a time course study, indicating that BrdU-
labeled cells are constantly dividing under the culture conditions used.
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Figure 2. TNFα-stimulated BrdU+ cell proliferation
Top panel: Time course study of BrdU proliferation showing that TNFα (25 ng/ml)
stimulates a robust increase in BrdU+ cell populations. Data are presented by percentage
change relative to control * p<0.001 compared to Control, n = 6-8 slices). Bottom panel:
Representative images of BrdU immunohiochemistry are shown in Control (A) and TNFα
(B) at 48 hr time point (Scale bar = 500 μm). The confocal z-section images shown are the
double immunofluorescent staining of BrdU (green) and microglial marker Iba-1 (red)
(original magnification 40x). The bar graph to the upper right depicts BrdU+ IR at 48 hr
time point measured from control- and TNFα-treated groups (n = 6-8). Bar graph on the
bottom right represents the percentage of BrdU+ cells co-expressing Iba-1.
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Figure 3. ATP-P2X7 receptor signaling regulates basal proliferation of BrdU+ cells
A: After BrdU treatment, slices were incubated with ATPase apyrase (APY: 1, 10, and 50
U/ml) or NTPDase inhibitor ARL 67156 (ARL: 1, 10, and 50 U/ml) for 48 hr and then BrdU
+IR determined. Lowering extracellular ATP level by APY inhibits while increasing
extracellular ATP level by ARL augments basal proliferation of BrdU+ cells under normal
culture conditions used. B: After BrdU treatment, slices were with P2X7R agonist BzATP
(10, 50, 100, and 300 μM) or antagonist oxATP (10, 50, 100, and 300 μM) for 96 hr and
then BrdU+IR was determined as described in the methods. Activation of P2X7R with
agonist BzATP or blockade of P2X7 receptors with antagonist oxATP dramatically increases
or decreases proliferation of cells labeled by BrdU in a dose dependent manner respectively
(* p<0.001 comparing to control). C: After BrdU treatment, slices were cultured with the
presence of other P2X7R antagonists KN62 (50 μM) and BBG (100 μM) or P2X4R
antagonist suramin (100 μM) or agonist invemectin (IVM: 50 μM). The experiments were
repeated at least three times with similar designs and results.
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Figure 4. Cell type expression of P2X7 receptors in HEC slices
Panel A: The double immunofluorescent staining of anti-BrdU (green) and anti- P2X7 (red)
shows that the majority of BrdU+ cells co-expressing P2X7R (A-20x; A1-2-80x; A3-120x).
Panel B: The double immunofluorescent staining of anti-OX42 (green) and anti- P2X7 (red)
shows co-localization of P2X7Rs in OX42+ microglial cells (B-20x; B1-2-80x; A3-320x).
Panel C: The double immunofluorescent staining of anti-NeuN (green) and anti- P2X7 (red)
shows strong expression of P2X7R on granule neurons of the hippocampus (C-20x;
C1-2-120x; C3-320x). Panel D: The double immunofluorescent staining of anti-GFAP
(green) and anti- P2X7 (red) shows expression of P2X7R in GFAP+ astrocytes (D-20x;
D1-2-80x; D3-160x).
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Figure 5. TNFα induction of P2X7 receptors
Panel A: Representative photographs of the double immunofluorescent staining with anti-
BrdU (green) and anti-P2X7R (red) show strong expression of P2X7Rs in BrdU+ cells in
TNFα-treated slices (A1-20x; A2-3-80x; A4-240x). Panel B: Bar graph indicates TNFα-
induced expression of P2X7R mRNA (* p<0.0001, n = 3). Panel C: Shown in bar graph are
mean ± SEM of mRNA levels of NTPDase family (n = 3).
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Figure 6. Proliferative action of TNFα is sensitive to the blockade of ATP- P2X7 receptor
signaling
Shown in bar graph (top) are mean ± SEM of BrdU+IR measured from each group (*
p<0.0001, compared to control; ** p>0.001, compared with TNFα treatment (48 hr), n =
6-8). TNFα-increased proliferation of BrdU+ cells significantly blocked by P2X7R
antagonists KN62 (K, 50 μM), BBG (B, 100 μM) and OxATP at 100 and 300 μM (oxA1
and OxA3) as well as by ATPase apyrase at 25 and 50 U/ml (A25 and A50), but not by
P2X4R agonist suramin (Su: 100 μM). The experiments were repeated three times with
similar designs and results. Representative images shown in bottom were taken from (A)
control, (B) TNFα treatment, (C) TNFα + oxATP300 μM, and (D) TNFα+Apyrase 50U
(Scale bar = 500 μm).
Zou et al. Page 20













Figure 7. Involvement of AQP4 in proliferative actions of TNFα
Bar graph (top) showing strong induction of AQP4 mRNA by TNFα, which was blocked by
the P2X7R antagonist oxATP and the PKC inhibitor H-7 (* p<0.001, compared to TNFα-
treated group, n = 3). Bar graph in the bottom showing TNFα-stimulated increases in BrdU
+IR was blocked by H-7 (50 μM) and AQP4 channel inhibitor TEA (50 and 100 μM) as
well as AQP4 siRNA, suggesting that AQP4 is involved in TNFα regulation of BrdU+
progenitor cell proliferation through activation of P2X7Rs. The experiments were repeated
with similar designs and results.
Zou et al. Page 21













Figure 8. Blockade of downstream signaling cascade ERK and p38MAPK inhibits TNFα-
stimulated BrdU+ cell proliferation
BrdU-treated slices were incubated with either p38MAPK inhibitor SB 203580 (SB: 50 μM)
or the Erk inhibitor PD 98059 (50 μM) in the absence or presence of TNFα (25 ng/ml) for
48 hr and BrdU+IR determined. Shown in bar graph (top) are mean ± SEM of BrdU+IR
measured from each group (* p<0.0001, compared to control; ** p>0.001, compared with
TNFα treatment, n = 5-8). The experiments with inhibitors were repeated three times with
the similar results. Representative images of BrdU+ IR were shown from each group as
indicated (Scale bar = 500 μm).
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Figure 9. ATP-P2X7 receptor signaling controls the proliferation of BrdU+ progenitors
ATP/BzATP activation of P2X7 receptor-downstream signaling cascades promotes basal
proliferation of BrdU+ cells. Apyrase functionally hydrolyses ATP to ADP/AMP (for
review Fields and Burnstock, 2006) and thus lowers extracellular ATP level limiting action
of P2X7Rs leading to reduction of BrdU+ cell proliferation. NTPDase family also
hydrolyses ATP to ADP/AMP (for review Fields and Burnstock, 2006)g to lower the
extracellular ATP level. ARL 67156 is an inhibitor of NTPDase family and subsequently
elevates extracellular ATP level leading to increased activation of P2X7Rs and BrdU+ cell
proliferation. Blockade of ATP-P2X7 receptor by using the P2X7R antagonists oxATP,
BBG or KN62 can shut down proliferation of BrdU+ progenitors. TNFα strongly induces
expression of P2X7 R and AQP4 mRNA and in turn increases BrdU+ progenitor
proliferation. Proliferative actions of TNFα can be abolished by blocking either P2X7Rs or
AQP4. TNFα-induced AQP4 expression may be influenced by P2X7Rs because the P2X7R
antagonist oxATP can eliminate TNFα induction of AQP4 and subsequent BrdU+ cell
proliferation. Inhibition of downstream signaling cascades abolishes proliferative actions of
TNFα.
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